Annovis Bio, Inc.
- ANVS
- NYSE
- Biotechnology
- Neurodegenerative Disease Therapies
- Alzheimer's/Parkinson's Drugs
- Clinical-Stage Biopharma
$0.96
Today −3.36%Quote Oct 19, 2026, 08:00 PM UTC
−14.04%over the last month
Max drawdown −29.0%From 1-month high −29.0%3 months −44.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Annovis Bio
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases.
Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
Employees
7
Founded
2008
Market value
$41.0M
Quote Oct 19
Floor
$0.92
4.5% below price
Resistance
$1.06
10.8% above price
Price vs analyst targets
9 analysts
Lowest target
$21.00Highest target
$30.00
$21.00Highest target
$30.00
- Price $0.96
- Average target $25.67
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 2574% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ANVSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free